Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low to Intermediate-1 MDS”

34 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 34 results

Large-scale testing (Phase 3)Ended earlyNCT00804050
What this trial is testing

Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts

Who this might be right for
Myelodysplastic Syndromes
Fondazione Italiana Sindromi Mielodisplastiche-ETS 184
Testing effectiveness (Phase 2)Ended earlyNCT00699842
What this trial is testing

A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients

Who this might be right for
Myelodysplastic SyndromeMDSLow to Intermediate-1 MDS+1 more
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 8
Testing effectiveness (Phase 2)Study completedNCT02268383
What this trial is testing

Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)

Who this might be right for
Myelodysplastic Syndromes
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 75
Testing effectiveness (Phase 2)Study completedNCT02363491
What this trial is testing

A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Opsona Therapeutics Ltd. 96
Large-scale testing (Phase 3)Active Not RecruitingNCT00843882
What this trial is testing

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Who this might be right for
AnemiaChronic Myelomonocytic LeukemiaDe Novo Myelodysplastic Syndrome+1 more
National Cancer Institute (NCI) 247
Early research (Phase 1)WithdrawnNCT02075034
What this trial is testing

Three Dosing Schedules of Oral Rigosertib in MDS Patients

Who this might be right for
Myelodysplastic Syndrome
Traws Pharma, Inc.
Testing effectiveness (Phase 2)Study completedNCT01015352
What this trial is testing

Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 98
Early research (Phase 1)Study completedNCT01062152
What this trial is testing

Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome
Telik 19
Testing effectiveness (Phase 2)Ended earlyNCT01459159
What this trial is testing

Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome (MDS)
Telik 162
Testing effectiveness (Phase 2)Study completedNCT00700206
What this trial is testing

Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome (MDS)
Telik 86
Large-scale testing (Phase 3)Ended earlyNCT00695396
What this trial is testing

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Who this might be right for
Myelodysplastic SyndromesAnemia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 25
Testing effectiveness (Phase 2)Ended earlyNCT00495547
What this trial is testing

SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
PETHEMA Foundation 16
Testing effectiveness (Phase 2)Study completedNCT00619099
What this trial is testing

Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndrome
Eisai Inc. 67
Testing effectiveness (Phase 2)Study completedNCT01048034
What this trial is testing

Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic Leukemia
Nordic MDS Group 30
Large-scale testing (Phase 3)Active Not RecruitingNCT02598661
What this trial is testing

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndromes
Geron Corporation 289
Testing effectiveness (Phase 2)Study completedNCT03011034
What this trial is testing

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Who this might be right for
Myelodysplastic Syndromes
Janssen Research & Development, LLC 34
Testing effectiveness (Phase 2)Ended earlyNCT02240706
What this trial is testing

Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Boehringer Ingelheim 27
Testing effectiveness (Phase 2)Study completedNCT02335268
What this trial is testing

Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia

Who this might be right for
Myelodysplastic Syndromes
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH 77
Testing effectiveness (Phase 2)Study completedNCT01338337
What this trial is testing

Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia

Who this might be right for
Myelodysplastic Syndrome (MDS)
Asociación Andaluza de Hematología y Hemoterapia 40
Testing effectiveness (Phase 2)Ended earlyNCT01422486
What this trial is testing

Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome (MDS)
Telik 2
Next Page